Incannex Healthcare has secured $3.3 million through a convertible debenture with Arena Special Opportunities, maturing on April 14, 2026. The funds will support the advancement of its pharmaceutical assets and operational growth, while a warrant allows Arena to purchase shares at a future price. Additionally, the company has obtained up to $60 million in funding through various agreements, enhancing its financial flexibility in the biopharmaceutical sector.
Incannex Healthcare Inc. (NASDAQ:IXHL) has secured a $3.3 million convertible debenture from Arena Special Opportunities, with net proceeds of approximately $2.88 million aimed at advancing its pharmaceutical assets and supporting operational growth. The company also received A$6.9 million for R&D expenses and up to $60 million in funding through various agreements, enhancing its financial flexibility. Despite recent stock volatility and a market cap of $41.64 million, Incannex continues to seek capital to bolster its position in the biopharmaceutical industry.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.